What is William Blair’s Estimate for Hologic Q1 Earnings?

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at William Blair cut their Q1 2025 earnings per share (EPS) estimates for Hologic in a research note issued on Monday, November 11th. William Blair analyst A. Brackmann now expects that the medical equipment provider will post earnings of $1.00 per share for the quarter, down from their previous forecast of $1.02. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic’s FY2026 earnings at $4.62 EPS.

HOLX has been the topic of several other reports. Mizuho dropped their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Royal Bank of Canada boosted their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Raymond James raised their price objective on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Evercore ISI boosted their target price on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. raised their price target on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and an average price target of $89.25.

Hologic Trading Up 0.5 %

NASDAQ:HOLX opened at $79.76 on Wednesday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock’s 50 day simple moving average is $80.88 and its 200-day simple moving average is $78.22. Hologic has a 12-month low of $67.59 and a 12-month high of $84.67. The firm has a market cap of $18.53 billion, a P/E ratio of 23.95, a PEG ratio of 2.50 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company posted $0.89 earnings per share.

Hedge Funds Weigh In On Hologic

A number of institutional investors have recently made changes to their positions in the stock. Innealta Capital LLC acquired a new stake in shares of Hologic during the second quarter valued at $25,000. Wolff Wiese Magana LLC acquired a new position in shares of Hologic in the third quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new stake in Hologic during the first quarter worth approximately $37,000. Sunbelt Securities Inc. purchased a new stake in Hologic in the 2nd quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. raised its holdings in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.